Shire's attention-deficit drug Daytrana shows shorter wear time

By Elaine Rigoli

Tampa, Fla., May 25 - Shire plc announced that its methylphenidate transdermal system (MTS), Daytrana, has significant efficacy in reducing the symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged six to 12 years during shorter wear times than the recommended nine-hour wear time, and that the effect of the medication significantly decreased with patch removal, according to the results of a phase 3b clinical trial.

"For physicians and parents who want individualized control of a patient's ADHD symptoms, our data show that ADHD symptoms still are significantly controlled when the ADHD patch is used for less than its recommended nine-hour wear time, but the effect of the medication decreases upon patch removal," said clinical trial principal investigator Timothy E. Wilens.

"Because the ADHD patch allows physicians to vary the duration of effect of the medication up to the recommended nine hours, this new treatment option adds an important dimension to the treatment of children with ADHD."

In April, the Food and Drug Administration approved Daytrana for once-daily use to treat ADHD in children aged six to 12 years old.

Daytrana was developed by Noven Pharmaceuticals, Inc., and combines the active ingredient, methylphenidate, with Noven's patented DOT Matrix transdermal technology.

London-based Shire is a specialty pharmaceutical company that focuses on meeting the needs of the specialist physician.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.